Table 4.
Complete response (%) by age, phase, and chemotherapy treatment following oral administration of rolapitant55,56
| Patients <65 years old
|
Patients ≥65 years old
|
|||||||
|---|---|---|---|---|---|---|---|---|
| MEC plus AC, %
|
P-value | Cisplatin-baseda, %
|
P-value | MEC- or AC-based, %
|
P-value | Cisplatin-baseda, %
|
P-value | |
| ROL (n=495) vs CON (n=470) | ROL (n=397) vs CON (n=393) | ROL (n=171) vs CON (n=196) | ROL (n=138) vs CON (n=142) | |||||
| Acute phase (0–24 h) | 81.8 vs 77.9 | 0.127 | 81.9 vs 76.8 | 0.082 | 88.3 vs 86.2 | 0.553 | 88.4 vs 76.1 | 0.007 |
| Delayed phase (24–120 h) | 70.3 vs 60.9 | 0.002 | 71.3 vs 59.8 | <0.001 | 74.3 vs 63.3 | 0.024 | 71.7 vs 61.3 | 0.064 |
| Overall phase (0–120 h) | 67.5 vs 56.6 | <0.001 | 68.0 vs 58.5 | 0.006 | 71.9 vs 60.7 | 0.024 | 71.0 vs 58.5 | 0.028 |
Note:
a
Pooled analysis of the two HEC phase 3 trials.
Abbreviations: AC, anthracycline and cyclophosphamide; CON, control; h, hours; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ROL, rolapitant.